We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Two plans — one from Operation Warp Speed and one from the Centers for Disease Control and Prevention — for distributing a COVID-19 vaccine are short on crucial details and leaves much of the distribution to state and local authorities. Read More
Novavax President and CEO Stanley C. Erck said the company anticipates starting phase 3 efficacy trials around the world “in the coming weeks.” Read More
Novavax has expanded its COVID-19 vaccine manufacturing agreement with the Serum Institute of India to produce more than 2 billion doses of the vaccine annually. Read More
Gilead Sciences has announced that it will spend $21 billion to acquire New Jersey drugmaker Immunomedics as part of its ongoing expansion into immune-oncology treatments. Read More
As the race for COVID-19 vaccines intensifies, the unprecedented problems of distributing them once they get regulatory approval are coming into focus — including the need for refrigeration throughout the supply chain. Read More
Pfizer and BioNTech are nearing the finish line for a COVID-19 vaccine supply agreement with the European Commission (EC), wrapping up exploratory talks Wednesday and beginning the contract negotiation process for 200 million doses of their candidate. Read More